- About
-
Services
-
Offerings
- Offerings
- ADME and Bioanalytical Sciences
- Analytical Chemistry
- Assay Development
- Biochemical Assays
- Biophysical Assays
- Cell Based Assays
- Computational Chemistry
- Fragment and Compound Screening
- Integrated Drug Discovery Services
- Medicinal Chemistry
- Protein Expression and Purification Services
- Structural Biology
- Synthetic Chemistry
- Virtual screening
-
Research Phases
- Research Phases
- Hit Identification
- Hit to Lead
- Lead Optimisation
- Therapeutic Areas
- Target Classes
-
Approaches & Techniques
- Approaches & Techniques
- CDH (Target Gene Fragmentation)
- Cryogenic Electron Microscopy (Cryo-EM)
- Differential Scanning Fluorimetry (DSF) and nanoDSF Services
- Direct-to-Biology (D2B)
- eProtein Discovery
- Flow Cytometry
- Fragment Based Drug Discovery (FBDD)
- FragmentBuilder
- Grating-Coupled Interferometry
- High Throughput Screening
- Isothermal Titration Calorimetry (ITC)
- LeadBuilder
- PoLiPa (Membrane Protein Solubilisation)
- Spectral Shift and MST Services
- Structure Based Drug Design (SBDD)
- Surface Plasmon Resonance (SPR)
- X-ray Crystallography
-
Offerings
- Library
- News & Events
- Careers
Join our webinar series discussing the latest developments in drug discovery. Register now.
Enquire
14th Annual Healthcare Investor Conference
Thursday, 6 Oct '22
Now in its 14th year, the Annual Healthcare Investor Conference is firmly established as a major thought leadership event in Europe, bringing together the top executives and visionaries from the healthcare industry and investment community to discuss and debate the trends set to reshape the industry far into the future.
Tom Mander (Domainex's CEO) will be attended the event at Wellcome Collection in London.
News
Start your next project with Domainex
Contact one of our experts today